EPCAM and cancer: At the REL stage, the majority of cancer cells reverted to an EpCAM+ epithelial phenotype following both protocols (Fig. 6E), suggesting that a substantial subset of the few surviving tumor cells in immunocompetent hosts had undergone a transient loss of epithelial characteristics.